DGAP-News: Eckert & Ziegler: Sales Growth and Strong Operating Result in the First Quarter


 
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results/Forecast Eckert & Ziegler: Sales Growth and Strong Operating Result in the First Quarter 10.05.2016 / 07:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, 10 May 2016. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, reported sales of EUR 35.8 million (+6%) in the first quarter of 2016. All segments registered organic growth. However, the previous year's EBIT level could not quite be achieved as the prior-year period included a positive currency effect of EUR 1.3 million, meaning that EBIT declined by EUR 0.9 million to EUR 4.3 million. Earnings after minority interests fell by EUR 0.2 million to EUR 2.5 million, or EUR 0.47 per share. The Isotope Products segment showed the strongest growth with EUR +1.6 million. At slightly higher costs, EBIT was 5% below the prior year at EUR 3.5 million. As of 2016, the Isotope Products segment includes Environmental Services which was previously reported under the Others segment. For comparative purposes, the prior year's figures have also been adjusted accordingly. In the Radiation Therapy segment, as expected, sales declined due to the disposal of the US implant division. Organic growth was achieved with the new SagiNova(R) tumor irradiation device. After a long time, the segment achieved balanced operating results once again. One-off effects of EUR -0.3 million each for expenses from the disposal of the US division and a negative currency effect led to an EBIT of EUR -0.6 million. Sales grew in the Radiopharma segment, particularly with gallium generators. The cyclotron division, on the other hand, registered a downward trend during the whole of 2015. However, this trend reversed in the first quarter of 2016. Sales and earnings generated with cyclotron products for diagnosing cancer and Alzheimer's disease almost achieved the level seen in the first quarter of 2015. EBIT rose by EUR 0.1 million to EUR 1.5 million. Operative cash flow increased by 31% to EUR 0.8 million. This effect is due to a good result for the period, which in contrast to the previous year does not include non-cash results. Compared to 2015, more or less constant sales of EUR 140 million are expected for 2016. Profit is likely to decline to around EUR 1.80 per share due to the absence of positive one-off effects. The complete quarterly financial statements can be viewed under: http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl isch/euz116e.pdf About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 700 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine. Contributing to saving lives. For further information or questions, please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com --------------------------------------------------------------------------- 10.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: [email protected] Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich End of News DGAP News Service --------------------------------------------------------------------------- 461707 10.05.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 36,040 Halten 763,04
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
22,53 26,26 0,89 40,15
KBV KCV KUV EV/EBITDA
3,45 16,10 3,10 12,45
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 0,05 0,14 28.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2024 09.08.2024 14.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-8,44% -2,95% -12,74% -22,89%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ